Drug intelligence / Profile preview

[68Ga]Ga-NOTA-ABDG2

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-NOTA-ABDG2 is a gallium-68 labeled radiopharmaceutical developed for the immuno-positron emission tomography (immunoPET) imaging of hepatocellular carcinoma (HCC). The agent targets Glypican 3 (GPC3), a cell-surface proteoglycan that is highly and specifically expressed in HCC tissues. Structurally, the probe consists of a GPC3-specific single-domain antibody (sdAb), known as G2, which is fused to an albumin-binding domain (ABD) to optimize its pharmacokinetic profile. The ABD fusion serves to extend the circulatory half-life and reduce renal uptake, addressing common limitations of small antibody fragments. The protein is conjugated to the chelator NOTA to facilitate labeling with the positron-emitting isotope Gallium-68. Preclinical studies indicate that [68Ga]Ga-NOTA-ABDG2 provides high-contrast imaging of GPC3-positive tumors, making it a potential candidate for the diagnosis and staging of HCC.

Other names: 68Ga-NOTA-ABDG2Gallium-68 NOTA-ABDG2Gallium68 NOTA-ABDG2Gallium 68 NOTA-ABDG2

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on [68Ga]Ga-NOTA-ABDG2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-NOTA-ABDG2.

Explore the full profile